Janus Henderson Group PLC Cuts Stake in Evolent Health, Inc. (NYSE:EVH)

Janus Henderson Group PLC cut its holdings in Evolent Health, Inc. (NYSE:EVH) by 16.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,850 shares of the technology company’s stock after selling 8,400 shares during the period. Janus Henderson Group PLC’s holdings in Evolent Health were worth $1,241,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. William Blair Investment Management LLC lifted its holdings in shares of Evolent Health by 35.2% in the second quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after buying an additional 1,308,376 shares in the last quarter. First Light Asset Management LLC lifted its stake in Evolent Health by 401.5% in the 2nd quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company’s stock worth $27,634,000 after purchasing an additional 1,157,124 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Evolent Health by 59.9% during the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after purchasing an additional 1,000,215 shares during the last quarter. Engaged Capital LLC grew its position in shares of Evolent Health by 26.1% during the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock valued at $78,611,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Evolent Health by 24.8% in the second quarter. Bank of New York Mellon Corp now owns 2,048,341 shares of the technology company’s stock worth $39,164,000 after purchasing an additional 406,837 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Oppenheimer cut their price target on Evolent Health from $34.00 to $28.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Barclays reduced their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. BTIG Research lowered their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. Citigroup reduced their target price on shares of Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a report on Tuesday, November 12th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $26.18.

Evolent Health Trading Down 0.2 %

Shares of NYSE EVH opened at $11.38 on Friday. Evolent Health, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -12.50 and a beta of 1.45. The business’s 50 day moving average price is $18.18 and its 200-day moving average price is $22.53.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.